Malta - English - Medicines Authority

mylan products limited - clarithromycin - coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

mylan products limited - clarithromycin - modified-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - clarithromycin - modified-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections due to susceptible organisms. such infections include. 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. is indicated also for the prevention of disseminated mycobacterium avium complex infection in hiv- infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include:
lower respiratory tract infections for example bronchitis and pneumonia.
upper respiratory tract infections for example sinusitis and pharyngitis.
skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - injection, powder, for solution - 500 mg/vial - clarithromycin 500 mg/vial

Malta - English - Medicines Authority

abbott laboratories limited - clarithromycin 500 mg - film-coated tablet

Malta - English - Medicines Authority

abbott laboratories limited - clarithromycin 500 mg - modified-release tablet

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - clarithromycin; omeprazole; amoxycillin -